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1. Introduction 
Malignant melanoma is an aggressive malignancy responsible for nearly 60% of death from 
skin cancers. Recent advancements in the biology and molecular genetics of melanoma are 
accompanied by an improved appreciation of the roles of both intrinsic and extrinsic risk 
factors in their contribution to disease. This chapter reviews the epidemiology, risk factors, 
and clinical phenotypes of melanoma.  
2. Melanoma epidemiology 
Over the past two decades we have observed increases in the incidence of malignant 
melanoma in the Caucasian population, while overall mortality rates have remained 
somewhat stable. The incidence and mortality of melanoma is considered in terms of 
geography and ethnicity using data from the United States and worldwide. 
2.1 U.S. melanoma epidemiology 
Melanoma trends in the United States were examined using data from the Surveillance, 
Epidemiology, and End Results (SEER) Program, a National Cancer Institute program that 
collects cancer and survival data from approximately 26% of the U.S. population. The SEER 
data revealed an increase in age-adjusted incidence rates of melanoma, which more than 
doubled among females and nearly tripled among males between 1973 and 1997 (Jemal et 
al., 2001). After an additional 7 years of SEER data, it was found that among young adults 
(aged 15–39 years) there was an increase in melanoma incidence among young women, and 
the authors suggested a possible role of ultraviolet radiation exposure, as discussed in 
further detail below (Purdue et al., 2008). Melanoma incidence has increased at 3.1% per 
year, with increases in tumors of all subtypes and thicknesses, and non-significant increases 
in melanoma mortality (Linos et al., 2009). The median age of melanoma diagnosis is 60 
years, with an age-adjusted incidence of 20.1 per 10,000 individuals, from 2003–2007 (SEER 
website, accessed 2011).  
There are differences in melanoma incidence and mortality dependent upon ethnicity. The 
SEER data shows the highest incidence among Caucasians (19.1 females and 29.7 males per 
100,000), followed by Hispanics (4.7 females and 4.4 males per 100,000), American 
Indians/Alaska Natives, Asian/Pacific Islanders, and Blacks (1.0 females and 1.1 males per 
100,000)(SEER website, accessed 2011). Incidence data are depicted in Figure 1. Among U.S. 
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Hispanics and non-Hispanics from 2004–2006, it was noted that Hispanic melanoma 
patients had poorer prognostic characteristics (stage, tumor depth, and ulceration) at the 
time of diagnosis (Merrill et al., 2011). Comparing the same ethnic groups over different 
regions of the country, male Hispanic Floridian patients had a 20% higher and non-Hispanic 
black Floridian patients had a 60% higher incidence of melanoma compared to non-Florida 
patients of the same gender and ethnicity (Rouhani et al., 2010). The SEER data projected 
that, in 2010, there would be 68,130 new melanoma diagnoses and melanoma-related deaths 
among 8,700 men and women (SEER website, accessed 2011). The median age at death is 68 
years, with the highest death rates among the U.S. Caucasian population (2.0 females and 
4.5 males per 100,000), followed by American Indian/Alaska Natives, Hispanics, Blacks, and 
Asian/Pacific Islanders, from 2003–2007 (SEER website, accessed 2011). Overall mortality is 
depicted in Figure 1. African American patients with melanoma have poor overall survival 
outcomes, which were not explained by external factors such as treatment discrepancies or 
socioeconomic status (Zell et al., 2008). One plausible contributor is the anatomic 
distribution of melanomas in patients of differing cutaneous pigmentation. Whereas 
melanomas are most likely to occur on typical cutaneous surfaces in Caucasians, they are 
proportionally more common (though of similar overall incidence) on acral (hairless) or 
mucosal surfaces among darkly pigmented individuals—surfaces commonly associated 
with thicker lesions at diagnosis. 
 
 
Fig. 1. Melanoma Incidence and Mortality Rates in the United States from 1975-2007.  Data 
was extracted from the SEER database (SEER website, accessed 2011).  
2.2 Global melanoma epidemiology 
Data from a variety of countries and latitudes show similar trends in the incidence of 
melanoma. The role of geographic latitude on sun exposure was examined through pooled 
analysis of case-control studies including 5,700 melanoma cases (Chang et al., 2009a; Chang 
et al., 2009b). A meta-analysis of risk factors for cutaneous melanoma found that latitude is 
an important risk factor for melanoma (P=.031), and higher latitudes (distant from the 
equator) conferred an increased risk for sunburns (another melanoma risk factor), possibly 
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due to intermittent intense sun exposure (Gandini et al., 2005a). The role of sun and 
ultraviolet exposure will be explored in further detail below. 
Epidemiological data on melanoma incidence is available from a number of countries. In 
Australia between 1990 and 2006, there was a stabilization of the thin melanoma rate, and 
the highest rates of melanomas occurred in the northern tropical regions; however, there 
was also an increase in the number of thick melanomas, particularly in the southern regions 
(Baade et al., 2011). The authors speculated that the decrease in thick melanomas may be 
positively affected by early detection and skin awareness campaigns (Baade et al., 2011).  
A 10-year study of melanoma in a central England population revealed an increase in thin 
melanoma, particularly among younger patients, and a slower increase in thick (>4mm) and 
intermediate (1.01–4mm) melanomas (Hardwicke et al., 2011). In Northern Ireland, a 
seasonal variation of melanoma diagnosis timing suggested that incidence of cutaneous 
melanoma is highest in the summer; the trend was most prominent for women (Chaillol et 
al., 2011). Analysis of malignant melanoma incidence in Turkey from 1988–2007 showed a 
median age of melanoma diagnosis of 52 years and statistically significant increases of 
melanoma incidence with increasing age (Tas, 2011).  
Global data for melanoma is available from the World Health Organization (WHO), which 
states that the incidence of melanoma has been increasing over the past decades, with 132,000 
melanomas occurring globally each year (WHO website, accessed 2011). The annual incidence 
increase varies among populations (estimated 3–7%), while overall mortality rates have been 
increasing at a lesser rate (Diepgen and Mahler, 2002; Lens and Dawes, 2004). From the mid-
1950s through the mid-1980s, melanoma mortality rose among young and middle-aged adults 
in most of Europe, North America, Australia, and New Zealand (La Vecchia et al., 1999). 
Between 1985 and 1995, there was a continued increase in mortality (though at lesser rates) in 
middle-aged men and declining mortality rates in middle-aged women in northern Europe, 
North America, Australia, and New England (La Vecchia et al., 1999). Overall global increases 
in cutaneous malignant mortality were reported in 2000, based upon data from countries with 
a minimum time series of 30 years and 100 deaths annually in one sex from melanoma. This 
analysis revealed small decreases in mortality rates in Australia, Nordic countries, and the 
United States; lesser decreases in the United Kingdom and Canada; and ongoing increases in 
melanoma mortality rates in France, Italy, and Czechoslovakia (Severi et al., 2000). Mortality 
also continued to increase among patients in Spain (Nieto et al., 2003). Regional and worldwide 
campaigns to increase melanoma awareness have been launched, as survival is associated with 
thickness of lesion at the time of diagnosis. 
2.3 Trends in melanoma epidemiology data 
There exists some debate over the explanation for the observed trends in epidemiological 
measures, which suggest overall increases in disease incidence, with some stabilization of 
mortality rate over time. Likely there is some contribution associated with longer life 
expectancy and improved detection of cancer (Balducci and Beghe, 2001); however, the 
debate among experts continues as to whether there is a true increase in disease versus 
better detection with improved surveillance (Lamberg, 2002). It has been questioned 
whether the increased disease surveillance programs have succeeded to identify melanomas 
with more indolent behavior (Swerlick and Chen, 1996), as it is shown that the incidence of 
biopsy rates between 1986 and 2001 was associated with an increase in diagnosis of in situ 
and local melanomas, but not the incidence of advanced melanomas, in nine geographical 
areas of the United States (Welch et al., 2005). More frequent thinner melanoma detection 
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was also noted in Germany and France (Lasithiotakis et al., 2006; Lipsker et al., 2007). A 
large-scale prospective randomized survival-based study has not been carried out to prove 
benefit of skin cancer screening—although the requirement for such a study, or the ethics of 
being randomized to a non-screening arm, remains controversial. 
While the expansion of skin screening programs may have increased the detection of 
relatively indolent melanomas, other studies have found that there are also increases in 
melanomas of all thicknesses (Linos et al., 2009), so the detection of more histologically 
aggressive melanomas may be increasing as well. To address concern that the histological 
diagnosis of melanoma has drifted over time, with lesions classified more severely over 
time, a large 9-country review of pigmented lesions was conducted. This study examined 
diagnoses of pigmented lesions between approximately 1930 and 1980 and found only a 
2.8% shift of melanoma cases from benign to malignant classification (van der Esch et al., 
1991), thus the increased disease incidence cannot be solely attributed to drift in histological 
interpretation. The debate over whether the increase in melanoma incidence reflects a true 
“melanoma epidemic” is also complicated by a number of biases and controversies, 
including surveillance intensity, length-time bias, diagnostic uncertainty, the cancer-relevant 
medico-legal climate, and problems related to data collection and recording (Swerlick and 
Chen, 1997; Florez and Cruces, 2004). Questions have been raised regarding a potential 
underreporting of melanoma over time, with estimates as high as 17% in the SEER database 
(Purdue et al., 2008). Regardless of the interpretation of epidemiology measures, these 
studies have offered insights on trends in melanoma incidence and mortality, in addition to 
the intrinsic and extrinsic risk factors that are increasingly important in the management 
and prevention of future disease. 
3. Melanoma risk factors 
Melanoma risk factors include both intrinsic (genetic and phenotype) and extrinsic 
(environmental or exposure) factors. While intrinsic factors are inherent to the patient and 
cannot be modified, it is important to identify the at-risk population of patients. Conversely, 
extrinsic factors, from environment to behaviors, should be examined and minimized as 
possible, especially for the population with intrinsic increased melanoma risk. Major risk 
factors for melanoma include ultraviolet radiation exposure, family history, nevi (dysplastic, 
large number, or giant congenital nevi), increased age, fair skin phototype, occupation, and 
BMI (Rigel, 2010).  
3.1 Intrinsic risk factors  
Intrinsic melanoma risk factors are non-modifiable attributes that influence one’s risk of 
melanoma, including age and gender, Fitzpatrick skin phototype (which is a gauge of one’s 
skin color and burning or tanning response to sun exposure), and nevi pattern (quantity, 
size, clinical atypia, or dysplasia), which are readily apparent on examination. Also 
considered are the impacts of a patient’s family history of melanoma, personal history of 
skin cancer, and underlying medical conditions including obesity, immunosuppression, 
cancer, and Parkinson’s disease. 
3.1.1 Age and gender  
Melanoma is among the most rapidly rising cancers in the United States, with highest 
melanoma risk among elderly males (Jemal et al., 2001). There is a general increase in 
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lifetime melanoma risk with advancing age for both men and women (Psaty et al., 2010). 
Among patients with melanoma, the incidence of development of a second primary 
melanoma is 5.3% at 20 years and is also highest in older male patients (Goggins and Tsao, 
2003). Older patients were found to have lentigo maligna melanoma more often than 
younger patients, with 75% occurring on the head and neck (Elwood et al., 1987). Risk based 
upon sex is greater overall in males; however, incidence is higher in women until the age of 
40 and then greater in males, with a ratio of 2:1 males: females by age 80 (Rigel, 2010). The 
SEER dataset shows the highest mortality among elderly males in all races from 1992-2007, 
with a mortality rate of 30.9 per 100,000 among males over age 85, in contrast to the highest 
female mortality rate of 12.4 per 100,000 for patients over age 85. Elderly males have 
disproportionately greater melanoma mortality, with mortality rates that are greater than 
double the female mortality rate when comparing all age groups over 55 years (SEER 
website, accessed 2011).  
3.1.2 Skin phototype 
An increased risk of melanoma has long been associated with characteristics of low 
Fitzpatrick skin phototype, such as pale skin, blond or red hair, freckles, and tendency to 
burn and tan poorly (Bataille and de Vries, 2008). The greatest risk is among patients with 
red hair or fair complexions, followed by those who burn easily, tan poorly, and freckle 
(Rigel, 2010). Fitzpatrick phototype I skin versus phototype IV imparts a relative risk of 2.09 
of developing melanoma, with an increased relative risk for individual physical attributes 
such as fair skin color (2.06 versus dark), blue eye color (1.47 versus dark), red hair color 
(3.64 versus dark), and high density of freckles (relative risk of 2.10), as calculated by 
systematic meta-analysis of observational studies of melanoma risk factors (Gandini et al., 
2005b). A large prospective study from Norway and Sweden (>100,000 women) showed 
statistically significant risk of melanoma associated with hair color (red versus dark 
brown/black), in addition to other factors such as large body surface area (at least 1.79 m2) 
and number of large asymmetric nevi on legs (Veierod et al., 2003), as reviewed below. The 
genetics associated with a clinical phenotype of red-haired patients with melanoma is 
discussed in further detail in Section 4. 
3.1.3 Nevi  
Dysplastic nevi are markers for increased melanoma risk, for both the individual and his or 
her family (Rigel, 2010). The presence of more than 50 common nevi, dysplastic nevi, or 
large nevi is associated with increased melanoma risk. Pooled studies involving 5,700 
melanoma patients supported an increased risk with a nevus phenotype including greater 
whole body nevus counts, presence of clinically atypical nevi, or presence of large nevi, 
regardless of latitude (Chang et al., 2009b). Their data showed a strongly increased risk with 
the presence of large nevi on the body and arms, and it suggested that an abnormal nevus 
phenotype is associated with melanomas on intermittently sun-exposed body sites (Chang et 
al., 2009b). Clinically dysplastic nevi were associated with increased melanoma risk 
depending upon their number: One dysplastic nevus imparts 2-fold risk, while 10 or more 
dysplastic nevi impart a 12-fold increased risk of melanoma (Tucker et al., 1997). Presence of 
a scar was identified as an independent risk factor for melanoma, as a scar may suggest the 
prior removal of a clinically atypical nevus at the site (Tucker et al., 1997).  
Nondysplastic nevi are also associated with increased melanoma risk when there are a large 
number of nevi and/or giant pigmented congenital nevi. The presence of large numbers of 
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nondysplastic nevi confers a lesser risk than dysplastic nevi. Having many small nevi 
imparts approximately 2-fold increased risk, and the presence of both small and large 
nondysplastic nevi imparts a 4-fold risk (Tucker et al., 1997). Congenital nevi were not 
associated with increased melanoma risk (Tucker et al., 1997); however, giant pigmented 
congenital nevi (covering >5% body surface area) confer substantial melanoma risk 
(Swerdlow et al., 1995).  
3.1.4 Changing skin lesions 
Changing skin lesions are associated with melanoma risk, as 75% of melanoma patients 
presented with a symptom or complaint associated with their melanoma lesion, most 
commonly “increase in size” (Negin et al., 2003). Patient complaints that strongly associated 
with an increased Breslow depth of melanoma upon multivariate analysis include bleeding, 
pain, lump, itching, and change in size (Negin et al., 2003). 
3.1.5 Personal history of skin cancer  
An important risk factor for melanoma is having a prior skin cancer, of either melanoma or 
non-melanoma type. Among patients diagnosed with a primary melanoma, 11.4% will 
develop a second primary melanoma within five years, and the risk is further increased if 
the patient also has a positive family history of melanoma or dysplastic nevi (Ferrone et al., 
2005). Risk of a second primary cutaneous melanoma among melanoma patients is found to 
be 6.01 per 1,000 person years after analysis of 20 years of follow-up in Queensland from 
1982–2003 (McCaul et al., 2008). Analysis of a Swiss registry found the 20-year incidence of 
second primary melanoma to be 5% (Levi et al., 2005). 
A retrospective study of patients with multiple primary melanomas identified several risk 
factors for multiple melanomas such as early age at diagnosis, dysplastic nevi (diagnosed 
clinically or histologically), family history of dysplastic nevi or melanoma, and history of 
dysplastic nevus with a family history of melanoma (Stam-Posthuma et al., 2001). In a large 
prospective cohort study of Queensland patients, risk factors for development of a second 
cutaneous melanoma were found to be similar: high nevus count, high familial melanoma risk, 
fair skin, inability to tan, an in situ first primary melanoma, and male sex (Siskind et al., 2011).  
A prior diagnosis of non-melanoma skin cancer is generally indicative of a history of UV 
exposure, which is an extrinsic risk factor that will be discussed in detail below. Patients 
with a history of squamous cell carcinoma, basal cell carcinoma, or pre-malignant actinic 
keratoses are reported to have a relative risk of developing melanoma of 4.28–17 (Marghoob 
et al., 1995; Gandini et al., 2005b). Interestingly, other cutaneous neoplasms that don’t 
associate as strongly with ultraviolet exposure have also been associated with an increased 
melanoma risk. Patients with mycosis fungoides carry a relative risk of 15.3 for development 
of melanoma, which may be related to immunosuppression or pathophysiology caused by 
the disease and/or associated therapies (Pielop et al., 2003). In Merkel Cell Carcinoma, an 
increased risk for melanomas has not been established, though the high fatality and 
advanced age of Merkel Cell Carcinoma patients may reduce the opportunity to develop 
additional cancers (Howard et al., 2006).  
3.1.6 Family history of melanoma  
A family history of melanoma has long been associated with increased melanoma risk; 
having a primary relative with melanoma imparts a relative risk of 1.74 of developing 
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melanoma (Gandini et al., 2005b). The highest risk occurs when a parent has multiple 
melanomas, with a relative risk of 61.78 (Hemminki et al., 2003). The Familial Atypical 
Multiple Moles and Melanoma (FAMMM) syndrome describes a syndrome in which two or 
more primary relatives have multiple dysplastic nevi and a history of melanoma (Fusaro 
and Lynch, 2000). Often these patients carry mutations in the CDKN2A gene or the related 
pathway, as described below. Among melanoma prone-families followed prospectively, the 
cumulative risk of developing melanoma at a young age (before age 50) was 48.9% (Tucker 
et al., 1993), and close surveillance is recommended. As described below, a family history of 
melanoma may arise from shared environmental risks, rather than purely genetically based 
risks. 
3.1.7 Other personal medical history  
A variety of medical conditions beyond a personal history of cutaneous carcinomas have 
reported associations with melanoma. Inherent diseases are described in this section, while 
associations with medical treatments are considered external risk factors and discussed in 
further detail below. 
There may be an increased risk of melanoma with elevated body mass index, as a meta-
analysis of 141 articles revealed a statistically significant positive association between 
increased BMI and malignant melanoma in men, though not as strong of an association that 
exists for esophageal, thyroid, colon, or renal cancers (Renehan et al., 2008).  
Both the immune system and DNA repair mechanisms are known to have important roles in 
protection from melanoma. Accordingly, in AIDS, there appears to be elevated risk of 
melanoma, which is highest among men who have sex with men, according to analysis of 
population-based U.S. AIDS and cancer registries in 2009 (Lanoy et al., 2009). A history of 
organ transplantation carries increased melanoma risk, with melanoma occurring in 6% of 
adult transplant recipients and 14% of patients who received organ transplantation in 
childhood (Penn, 1996). However, non-melanoma skin cancers, particularly squamous cell 
carcinomas, present with higher frequency than melanomas after organ transplantation 
(Moloney et al., 2006). Organ transplantation also carries a risk of transmission from the 
donor organ if the donor was previously affected with melanoma, and a diagnosis of 
melanoma requires careful consideration about whether to donate, or to revise the recipient 
patient’s transplant immunosuppression regimen (Zwald et al., 2010). Another population at 
increased risk of melanoma includes patients with xeroderma pigmentosum, who have 
defective DNA repair capability and are diagnosed with melanoma at a 5% rate. In these 
patients, 65% of their melanomas occurred on locations exposed to ultraviolet radiation such 
as the face, head, or neck (Kraemer et al., 1987). Ultraviolet radiation is associated with gene 
mutations and increased melanoma risk as discussed in further detail below.  
A number of non-cutaneous carcinomas have been shown to have associations with 
melanoma. Among women with a history of previous breast cancer, there is a standardized 
incidence ratio of 1.4 signifying an increased risk for cutaneous malignant melanoma among 
a Swiss Cancer Registry including 9,729 breast cancer patients followed over 24 years (Levi 
et al., 2003). The Breast Cancer Linkage Consortium studied cancer risks in BRCA mutation 
carriers and found that BRCA2 mutation carriers have an increased risk of developing 
malignant melanoma (2.58 relative risk) (The Breast Cancer Linkage Consortium, 1999), 
while BRCA1 mutation carriers have an increased risk for colon cancer and prostate cancer, 
but no significant excesses in rates of cancers of other body sites (Ford et al., 1994). Patients 
with a history of chronic lymphocytic leukemia or non-Hodgkin’s lymphoma have an 
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increased risk of melanoma, as malignant melanoma is among the most common presenting 
second cancer in both patient populations (Travis et al., 1991; Travis et al., 1992).  
Associations with pancreatic carcinoma and renal cell carcinoma are explored based upon 
the discovery of gene mutations that are similar to those mutated in familial melanomas. In 
a study of familial pancreatic carcinoma families, 12% of these families carried a CDKN2A 
mutation (Lynch et al., 2002). There is also an association of patients with melanoma and 
renal cell carcinoma, as both types of cancer carry an increased risk for the other. A study of 
42 patients with both melanoma and renal cell carcinoma found a high frequency of positive 
melanoma family history, though the identification of only two CDKN2A mutant carriers in 
this series suggests that there may be a CDKN2A-independent genetic association involved 
(Maubec et al., 2011). 
A putative association between Parkinson Disease and melanoma has been controversial 
and was perhaps based on the fact that both diseases involve cells that metabolize tyrosine 
via dopaquinone intermediates (albeit using distinct enzymes, tyrosine hydroxylase vs. 
tyrosinase). Literature review does not offer evidence that levodopa therapy is associated 
with development of malignant melanoma (Pfutzner and Przybilla, 1997). In 1978, levodopa 
therapy, a mainstay of Parkinson Disease management, was examined in a prospective 
query of 1,099 melanoma patients; at the time of presentation, only one patient had been 
taking levodopa (Sober and Wick, 1978). A family history of melanoma conferred an 
increased multivariate relative risk of developing Parkinson Disease among 157,036 
individuals followed prospectively, with no associations between a family history of other 
major types of cancer or several environmental risk factors (Gao et al., 2009). In addition, a 
recent study showed an increased melanoma risk in patients with Parkinson disease 
(prevalence was 2.24-fold higher than age and sex-matched SEER population data), and it 
was recommended that these patients be followed closely for skin changes over time 
(Bertoni et al., 2010). 
3.2 Extrinsic risk factors  
In this section, external factors that are associated with melanoma risk are considered. 
Aspects of a patient’s social history, such as their occupation, socioeconomic status, and 
marital status, have been shown to impact melanoma risk, though the mechanism for these 
interactions is not well understood. The risk of ultraviolet exposure is more readily 
explained, and data have accumulated regarding the effects of both natural and artificial 
ultraviolet radiation. Medications and chemical exposures can influence melanoma risk, and 
new studies have examined whether medications can play a role in modification of one’s 
melanoma risk. 
3.2.1 Social history  
Analysis of 29,792 cases of melanoma in California for trends involving socioeconomic 
status showed that individuals who lived in areas of highest socioeconomic status were at 
increased risk for melanoma (Linos et al., 2009). Low socioeconomic status is also regarded 
as a poor predictor of melanoma outcomes and has been associated with disparities in 
utilization of sentinel lymph node biopsy (Zell et al., 2008; Bilimoria et al., 2009). Financial 
concerns were found to influence outcomes of disease in melanoma patients; a retrospective 
study found that perceived financial difficulty (compared to patients with an equivalent 
deprivation score) was related to recurrence risk, after adjusting for histological 
characteristics of the melanoma (Beswick et al., 2008). Examination of SEER data of 
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melanoma patients for the effect of marital status on melanoma stage, after controlling for a 
number of factors including histology, anatomic site, and socioeconomic status, suggested 
that unmarried patients had a higher risk of late-stage cutaneous melanoma diagnosis 
(McLaughlin et al., 2010).  
Occupation is associated with greater melanoma incidence in indoor workers and those 
with higher education, in addition to occupation-specific associations that have been 
observed utilizing cancer registries (Rigel, 2010). Analysis of cancer registries in England, 
Wales, and Sweden found the highest occupation-associated risk to be with airline pilots, 
finance and insurance brokers, professional accountants, dentists, inspectors, and 
supervisors in transport, with many of these professions sharing a high level of education 
(Vagero et al., 1990). Among males in a California cancer database that listed fire fighter as 
their occupation, there was an increased risk of melanoma, in addition to increased risks of 
testicular cancer, brain, esophageal, and prostate cancers, compared to other types of cancer 
(Bates, 2007). Occupation-specific non-solar exposures impart increased melanoma risks for 
workers in the petroleum, printing, electronics, automobile, and agricultural industries 
(Fortes and de Vries, 2008), and specific occupational chemical exposures are reviewed 
below. 
Those who are employed outdoors may have altered melanoma risk based upon ultraviolet 
exposure, an independent risk factor for melanoma. In 2005, Gandini et al. performed a 
meta-analysis and found an inverse association of high occupational sun exposure with 
melanoma (Gandini et al., 2005a), while others have shown that occupational exposure 
carries an increased risk of melanoma of the head and neck, especially at low latitudes 
(Chang et al., 2009a). The shift hours associated with one’s occupation has also been shown 
to impact melanoma risk, though the mechanism is not clear. Among 68,336 women in the 
Nurses’ Health Study from 1988–2006, there was a 44% decreased risk of skin cancer among 
nurses working 10 or more years on rotating night shifts compared to nurses who never 
worked night shifts, after adjustment for melanoma risk factors (Schernhammer et al., 2011).  
3.2.2 Ultraviolet exposure 
The International Agency for Research on Cancer (IARC) identified solar and ultraviolet 
radiation as a significant environmental risk factor for cutaneous malignant melanoma 
(IARC, 1992), and in 2009 an IARC working group classified UV-emitting devices as group 1 
carcinogens (El Ghissassi et al., 2009). Ultraviolet radiation reaching the earth’s surface is 
comprised of ultraviolet A and ultraviolet B radiation. Ultraviolet A light generally causes 
guanosine to thymine transversions, possibly due to oxidation of DNA bases (Pfeifer et al., 
2005). Ultraviolet B light characteristically generates mutations at dipyrimidine sequences 
with cytosine (which occurs in approximately 35% of p53 gene mutations). Overall, the 
ultraviolet radiation-induced DNA mutations render DNA repair machinery an important 
protection against melanoma, which is particularly problematic for patients with defective 
DNA repair. Some have raised concern that climate change and ozone depletion will lead to 
increased solar ultraviolet radiation exposure, which may further correlate with increases in 
skin cancer (Diffey, 2004). Recently, the 10-year follow-up of a prospective study of daily or 
discretionary sunscreen application showed that daily sunscreen use reduced the rate in 
total melanomas and significantly reduced the rate of invasive melanomas as well (Green et 
al., 2011). 
Recreational or intermittent sun exposure was associated with increased melanoma risk of 
the trunk and limbs, but not head and neck, regardless of latitude of residence (Chang et al., 
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2009a). Intermittent sun exposure is also associated with increased numbers of nevi (a 
potent melanoma risk factor) and nevi located at intermittently exposed body sites 
(Newton-Bishop et al., 2010). Solar (actinic) keratoses and reported sun exposure strongly 
influence melanomas localized to the head and neck, while sporadic intermittent exposures, 
blistering sunburns, and self-reported sunburns are associated with an overall increased 
melanoma risk on all major body sites (Olsen et al., 2010; Rigel, 2010). 
While intermittent sun exposure and a history of sunburns are associated with up to 65% of 
malignant melanomas, the cumulative ultraviolet radiation exposure and pattern are also 
significant considerations. In a systematic review of case-control studies, melanoma risk was 
positively associated with intermittent sun exposure and sunburn at all ages (adult, 
adolescence, and childhood), in contrast to a reduced rate of melanoma in individuals with 
high occupational ultraviolet exposure (Elwood and Jopson, 1997). Ultraviolet exposure 
pattern can also impart risk for specific melanoma subtypes. The lentigo maligna 
melanomas were less strongly related to intermittent sun exposure or skin reaction to sun, in 
contrast to superficial spreading melanomas and nodular melanomas. Of these types, 
superficial spreading melanomas were most strongly associated with vacation sun 
exposures (Elwood et al., 1987).  
3.2.3 Molecular features of mutations 
Although UV radiation is strongly associated with risk for development of melanoma, it is 
striking that signature UV mutations (pyrimidine dimers) are much less frequent within 
mutated oncogenes of melanomas than in non-melanoma skin cancers. An important 
terminology is used to discriminate genomic mutations which actively promote oncogenic 
behavior from those which are biologically silent. “Driver” mutations are functionally 
important in conferring cancerous phenotypic changes, whereas “passenger” mutations are 
indicative of carcinogenic exposure, but do not actively contribute to malignant behavior of 
the cell. A human melanoma was the first malignancy for which complete genomic 
sequencing was reported, and compared to a matched lymphocyte cell line derived from the 
same patient (Pleasance et al., 2010). In this study thousands of mutations were observed, 
including numerous pyrimidine dimers indicative of prior UV exposure. However 
comparatively few mutations were observed within gene coding regions (vs. intergenic 
zones of the genome) suggesting relatively efficient transcription-coupled DNA repair. 
Indeed the patterns of UV signature mutation were more informative about the molecular 
geneology of the tumor than the nature of its precise oncogenic “drivers.” 
3.2.4 Recreational tanning 
A recent study in Denmark examining travel and sun-related behavior from 2007–2009 
found that 69% of subjects tanned intentionally, and this was the most important factor in 
sunburn on vacation (Koster et al., 2011). Prospective data from The Women’s Lifestyle and 
Health Cohort Study including over 100,000 women from Norway and Sweden indicated 
that sunburns and solarium use (described below), particularly during adolescence and 
early adulthood (ages 10–39), are associated with increased melanoma risk (Veierod et al., 
2003). 
Typical 5-minute sunlamp tanning exposures increase melanoma risk by 19% for frequent 
users (over 10 sessions) and by 3% for occasional users (less than 10 sessions), with primary 
melanomas most commonly located on sites that are not generally exposed to sunlight 
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(Fears et al., 2011). Hery et al. described a significant increase in melanoma incidence in 
Iceland between 1954 and 2006, with increased incidence rates in women younger than 50 
years (Hery et al., 2010). They had postulated that UV-emitting tanning devices would 
increase melanoma incidence on the trunk (Boniol et al., 2004) and presented data suggestive 
of a possible influence of indoor tanning bed use on this increase (Hery et al., 2010). From 
1975–2006, SEER data revealed an increase in melanomas arising on the trunk among young 
women in the United States (Bradford et al., 2010). Examination of the Australian Melanoma 
Family Study data regarding indoor tanning bed use and melanoma risk identified 
associations of tanning bed use with increased early-onset melanoma, with increased risks 
for those who use tanning beds more frequently and at an earlier age (Cust et al., 2010).  
Several studies have indicated clear associations between indoor tanning and elevated 
melanoma risk. Lazovitch et al. observed increased melanoma risk in multiple groups of 
indoor tanning bed users (Lazovich et al., 2010). The data were in agreement with a prior 
meta-analysis of the same question published by the The International Agency for Research 
on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer (Int J. Cancer, 
2007). This study demonstrated elevated melanoma incidence in users of indoor tanning 
beds, and formed the basis for the subsequent designation of tanning beds as Class I 
carcinogens by the World Health Organization. An additional important aspect of indoor 
tanning is its association with addictive behavioral patterns. Studies by Feldman and 
colleagues revealed evidence of withdrawal-like symptoms in frequent tanning bed users 
who volunteered to receive a dose of the opiate antagonist naltrexone (Kaur et al., 2006). 
Frequent tanners were also able to discriminate UV-emitting tanning beds from “sham” 
tanning beds in a blinded study (Feldman et al., 2004). A recent questionnaire-based analysis 
of a cohort of frequent tanners indicated that 39% met DSM IV criteria for addiction to 
indoor tanning (Mosher and Danoff-Burg, 2010). The precise underlying mechanism(s) of 
this addiction remain to be determined, but it is plausible that such behaviors may underlie 
the unremitting increases in melanoma incidence described above. 
3.2.5 Medications  
Medications such as psoralens can artificially increase ultraviolet induced damage, 
significantly increasing melanoma risk. Patients receiving photochemotherapy with oral 
methoxsalen and ultraviolet A light have increased melanoma risk with a large number of 
treatments (at least 250), and the risk increases at 15 years after the first treatment (Stern et 
al., 1997) and appears to continue to increase with further passing of time (Stern, 2001). 
Some data exist for a decreased risk of melanoma with long-term (>5 years) use of 
cholesterol-lowering drugs in analysis of the Cancer Prevention Study II Nutritional Cohort 
from 1997–2007 (Jacobs et al., 2011), and higher doses of statin medications were associated 
with decreased melanoma risk upon analysis of a Vetaran’s Administration pharmacy 
database (Farwell et al., 2008). However, the effect of long-term statin use on melanoma risk 
was not evident upon analysis of the Kaiser Permanente database (Friedman et al., 2008).  
Female sex hormones and oral contraceptive use have been called into question regarding a 
potential increased risk of melanoma, given the slightly higher risk of breast cancer patients 
for melanoma (Levi et al., 2003), and the fact that estrogens can increase melanocyte counts 
and cause cutaneous hyperpigmentation. An examination of Nurses’ Health Study and 
Nurses’ Health Study II cohorts revealed a 2-fold increase in melanoma risk among oral 
contraceptive users, and a further increased risk among premenopausal women who took 
oral contraceptives for 10 or more years (Feskanich et al., 1999). Since that time, a number of 
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case reports and small cohort studies have offered conflicting information regarding 
hormonal therapy and melanoma risk. A Netherlands retrospective study found a 
cumulative dose-dependent increased risk of melanoma with hormone replacement therapy 
use (Koomen et al., 2009b), though the same authors found no association of estrogen use 
with increased anatomic thickness of cutaneous melanoma (Koomen et al., 2009a). Studies in 
mice demonstrated that the antiestrogen tamoxifen inhibited both development and 
metastasis in mouse melanoma (Matsuoka et al., 2009), though study of tamoxifen in 
patients with melanoma showed no improvement in overall response rate, complete 
response rate, or survival rate when administered with systemic chemotherapy (Lens et al., 
2003). Pregnancy had no influence on disease-free survival in patients with a history of stage 
I cutaneous malignant melanoma (Albersen et al., 2010).  
Pooled analysis of case control studies including 5,590 women found a lack of association 
between melanoma risk and pregnancy, and no relation between melanoma and exogenous 
hormone use (Lens and Bataille, 2008). Regarding the facts and controversies surrounding a 
hormonal influence on melanoma risk, at this time, exogenous hormone use is not 
contraindicated, though counselling should be performed on an individualized basis (Gupta 
and Driscoll, 2010). While the role of estrogens have not been definitively demonstrated in 
melanoma, some still suspect melanoma may be a hormone-related neoplasm (de Giorgi et 
al., 2011). 
3.2.6 Chemical exposures  
A possible association of melanoma exists with ionizing radiation, as well as chemicals and 
pollutants such as arsenic (Rigel, 2010). Occupational exposures to chemicals such as vinyl 
chloride, polychlorinated biphenyls, and petrochemicals have been linked to a possible 
increased risk of melanoma, though the contribution of these exposures to overall melanoma 
risk has not been consistently demonstrated in clinical studies (Markovic et al., 2007). Fortes 
and deVries have reviewed the literature for occupation-specific exposures with cutaneous 
melanoma and summarized the evidence implicating polycyclic aromatic hydrocarbons, 
benzene, and polychlorinated biphenyls; trichloroethylene solvents, dioxin, and polyvinyl 
chloride; pesticides; and ionizing and non-ionizing radiation (Fortes and de Vries, 2008). 
Agricultural pesticides including mancozeb, parathion, and carbaryl were shown to associate 
significantly with cutaneous melanoma after adjustment for confounding factors (Dennis et al., 
2010). There is concern that residential pesticide use may also impart increased cutaneous 
melanoma risk, as data from Italy supports a 2.18 odds ratio for high use of indoor pesticides 
(four times annually) versus low use (once annually) (Fortes et al., 2007). 
3.2.7 External factors and melanoma risk modification 
Recent prospective data offers a role for daily sunscreen use in the reduction of melanoma 
frequency and invasion (Green et al., 2011). Whereas prior studies had failed to consistently 
demonstrate such a benefit, this study incorporated 10-year followup, suggesting a longer 
latency between UV exposures for melanoma as compared to cutaneous squamous cell 
carcinoma. Additionally, attempts have been made to demonstrate benefit for 
supplementation of one’s diet with vitamin D or non-steroidal anti-inflammatory drugs, for 
which conclusive positive effect has not been demonstrated at this time. 
There remains controversy regarding the optimal level of serum vitamin D with respect to 
bone health, cancer, and wellness. A prospective cohort study suggested that vitamin D 
(serum 25-hydroxy-vitamin D3) levels are associated with lower Breslow thickness of 
www.intechopen.com
 
Melanoma Epidemiology, Risk Factors, and Clinical Phenotypes 
 
15 
melanoma at the time of diagnosis, as well as being protective of survival in terms of 
melanoma relapse and death independent of melanoma thickness (Newton-Bishop et al., 
2009). However, at this time, there are no data to indicate that supplementation with 
vitamin D after diagnosis is protective for melanoma (Hutchinson et al., 2010).  
Studies have explored a potential protective effect of non-steroidal anti-inflammatory drugs 
and acetylsalicylic acids, based on a chemopreventative effect for other cancer types in 
addition to promising in vitro laboratory studies that suggested a potential role in the 
inhibition of melanoma migration and invasion. A large, Dutch case-control study found 
that continuous use of low-dose acetylsalicylic acids imparted a significantly reduced 
incidence of melanoma in women, but not in men (Joosse et al., 2009). A large cohort study 
of self-reported NSAID use over the previous 10 years found no association between NSAID 
use and melanoma risk, tumor thickness, invasion, or metastasis, after statistical 
adjustments for melanoma risk factors and indications for NSAID use (Asgari et al., 2008).  
4. Melanoma clinical phenotypes 
For many years, scientists have noted that there are distinct sets of genetic alterations in 
melanoma, and some of these are associated with distinct clinical phenotypes. Several of the 
functionally important signalling pathways in melanoma are depicted in Figure 2. 
Mutations in either BRAF or NRAS are found in a significant majority of the most common 
cutaneous melanoma types, highlighting the importance of the RAS-RAF-MAPK-ERK 
signaling cascade in disease pathogenesis. A number of genes have emerged as therapeutic 
targets, but it is not yet known whether they have a particular phenotypic correlation. 
Conversely, clinical phenotypes such as lentigo maligna melanoma, melanomas arising in 
chronically sun-exposed skin, aggressive melanomas in the elderly, melanomas of unknown 
primary site, dysplastic, and amelanotic melanomas do not have a known specific genetic 
mutation at this time. There is an increasing appreciation of certain clinical phenotypes with 
genetic associations, and this knowledge may be leveraged for current and future 
therapeutic approaches. 
4.1 Intermittent ultraviolet exposures & sunburn-associated melanoma 
BRAF mutations are identified in over 60% of cutaneous melanomas (Smalley, 2010), with 
over 80% of these mutations characterized by an amino acid substitution (V600E mutation) 
(Davies et al., 2002). These melanomas often occur on skin with little histopathologic 
evidence of chronic sun damage (such as solar elastosis), occur in younger individuals, and 
are most associated with intense recreational/intermittent sun exposure (Junkins-Hopkins, 
2010). Comparison of the characterization of melanomas with and without marked 
microscopic solar elastosis (associated with chronic sun-induced damage) suggest that BRAF 
mutations were found in patients without chronic actinic damage, and NRAS mutations 
were found only in samples without BRAF mutation but were not specific for a melanoma 
subtype (Curtin et al., 2005). Analysis of Australian patients found that BRAF(V600E) 
mutation was significantly associated with a younger age at diagnosis of distant metastasis 
(56 versus 63 years) (Long et al., 2011).  
4.2 Melanoma in patients with red hair 
Individuals with red hair, pale skin, tendency to freckle, and the inability to tan are known 
to have specific melanocortin-1 receptor (MC1R) variant alleles, found in over 80% of 
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individuals with this pigmentation phenotype (Valverde et al., 1995). In 2000, an Australian 
study showed that patients with three active MC1R alleles (R151C, R160W, and D294H) 
have a doubled risk of cutaneous malignant melanoma for each active allele they carry. This 
increased risk persists among medium and dark-skinned individuals who carry one of the 
three designated MC1R variant alleles (Palmer et al., 2000). A meta-analysis on the nine most 
studied MC1R variants suggested that they may play a role in the pathogenesis of 
melanoma both via pigmentary and non-pigmentary mechanisms (such as generation of 
reactive oxygen species), as some of the variants were only associated with melanoma and 
not the pigmentary phenotype (Raimondi et al., 2008).  
Based upon their Fitzpatrick skin phototype, red-haired MC1R variant allele patients are 
particularly susceptible to environmental ultraviolet exposure and sunburns, and they 
should take precautions according to their increased melanoma risk. These patients may 
lack the phenotype of chronically sun-damaged skin (including microscopic solar elastosis), 
while acquiring a lifetime of intermittent intense ultraviolet exposure as described above. 
Accordingly, MC1R-melanoma risk has been associated with BRAF mutations. In a study of 
two Caucasian populations with non-chronic solar damage melanomas, BRAF mutations 
were identified in over 80% of patients with two variant MC1R alleles and in only 
approximately 30% of individuals with wild type MC1R (Landi et al., 2006). Patients 
carrying one or two MC1R variants in an Italian population were shown to have a 5–15 fold 
increase risk of BRAF-mutant melanomas regardless of actinic damage, and no BRAF-
negative melanomas were identified among this population (Fargnoli et al., 2008). 
4.3 Melanomas in specific locations: Uveal, acral, and mucosal melanomas 
Melanomas arising in specific locations are associated with specific genetic mutations. Uveal 
melanoma is characterized by distinct genetic mutations compared to cutaneous melanoma, 
as 83% of uveal melanomas exhibit somatic activation mutations of GNAQ or GNA11 
pathways, and they generally lack mutations in BRAF, NRAS, and KIT (Van Raamsdonk et 
al.. 2010). Oculodermal melanocytosis or Nevus of Ota is a risk factor for uveal melanoma 
(Singh et al., 1998), and uveal melanomas often metastasize to the liver (Singh et al., 2005). A 
large number of blue nevi contain similar genetic mutations (Van Raamsdonk et al., 2010). 
Acral and mucosal melanomas have been shown to possess more genomic instability and 
chromosomal aberrations (in terms of DNA losses or gains, changes in amplicons, or 
changes in total copy-number transitions)(Curtin et al., 2005). The c-KIT mutations are seen 
in up to one-third of acral and mucosal melanomas, in addition to those that arise in 
chronically actinically damaged skin (Curtin et al., 2006).  
4.4 Hereditary melanomas 
Among newly diagnosed melanoma patients, an estimated 5–10% have an affected primary 
family member. Familial melanomas account for ~10% of malignant melanomas and about 
half of these are associated with known genetic lesions. The hereditary melanoma syndrome 
may involve mutation in the cyclin-dependent kinase inhibitor 2A (CDKN2A) gene locus, 
imparting a loss or inactivation of p16 or its alternative reading frame gene (ARF) (Goldstein 
et al., 2006). Cell cycle regulator p16 protein mutations are found in 41% of familial 
cutaneous melanoma cases (Goldstein et al., 2006). The cyclin dependent kinase 4 (CDK4) 
enzyme, which is inhibited by p16 binding, is also found to be mutated in small sets of 
cutaneous melanoma families (Zuo et al., 1996). A microsphere-based array assay was 
recently developed to detect over 30 variants of p16 pathway mutations for genotyping of 
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familial melanoma samples (Lang et al., 2011).  Additional familial melanoma genes are 
being identified using high throughput genomics methodologies.  
 
 
Fig. 2. Cellular Signaling Pathways Relevant to Melanoma Clinical Phenotypes.  BRAF gene 
mutations disrupt Ras signaling in patients with intermittent/sunburn ultraviolet exposure, 
and are also more prominent among red-haired patients carrying MCR1 variant alleles.  
Uveal melanomas may carry activating mutations of GNAQ or GNA11, while mucosal and 
acral melanomas often have c-KIT mutations.  Hereditary melanomas with CDKN2A 
mutation have altered p16 pathway signaling.  Metastatic melanoma involves 
transformation of several of these and additional signaling pathways.  
4.5 Metastatic melanoma 
Advances in melanoma genetics have enabled the identification of key oncogenic pathways 
that promote the transformation of primary to metastatic melanoma. A number of cell cycle 
regulatory proteins have mutations that contribute to melanoma pathogenesis, such as AKT 
family member activation mutation in up to 43–60% of melanomas (Stahl et al., 2004) and 
loss of PTEN expression in 38% of primary and 58% of metastatic melanomas (Birck et al., 
2000). Constitutive activation of several other pathways may contribute to melanoma 
pathogenesis, including Src, JAK/STAT, Wnt, hedgehog, nuclear factor kappa B, and Notch 
signaling pathways (Smalley, 2010). A nested case-control study of DNA repair pathway 
genes in malignant melanoma patients and matched controls found a significant association 
of a PARP1 gene variant with melanoma risk (Zhang et al., 2011). 
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A number of oncogenic pathways have been targeted for therapies for malignant melanoma, 
including RAS/mitogen-activated protein (MAP) kinase family, RAF family members, 
MEK, c-KIT, and the P13K/AKT/mTOR pathways, in addition to downstream mediators of 
pathogenic pathways including apoptosis, anti-angiogenic, and immunological targets  
(Ko and Fisher, 2011). The MITF transcription factor is a lineage specific master regulator of 
melanocyte development and is amplified in ~20% of metastatic melanomas (Garraway et 
al., 2005). It is becoming increasingly apparent that targeting one established mutation (for 
example, the V600E mutation of BRAF or mutant KIT in acral/mucosal melanomas) can 
yield impressive therapeutic responses in some patients (Flaherty et al., 2010; Hodi et al., 
2008). Generally, the mutation-specific therapy provides a temporary improvement before 
disease progression, suggesting the potential for de novo mutations, activation of alternative 
signaling pathways such as NRAS or MAPK signaling, and evolution of melanoma 
(Johannessen et al., 2010; Nazarian et al., 2010). Clinical trials for combinatorial therapy 
targeting multiple pathways may provide improved therapeutic outcomes in patients who 
appear to develop tolerance or resistance to specific genetically-targeted therapeutic 
approaches (Solit and Sawyers, 2010), and one may consider evaluating the genome of 
progressing melanoma over time to enable improved personalized medicine, as is currently 
being pursued for other aggressive carcinomas (Singer, 2011). 
5. Conclusions 
With improved understanding of the risk factors and the relationship between clinical 
phenotype and genetics of melanoma, there are new opportunities for novel prevention 
strategies and therapeutic approaches for this devastating disease. Genome sequencing 
technologies have enabled the analysis and cataloging of somatic mutations from human 
cancers, and efforts are underway to expand this type of analysis to many additional 
melanomas in order to discriminate between driver and passenger mutations. Similar high 
throughput methodologies are being applied to populations at risk for melanoma formation, 
in order to identify predisposition genes and link them to specific environmental exposures 
or risks. Simultaneously, unprecedented progress has been made in translating the 
discovery of melanoma oncogenes into novel therapeutic strategies by exploiting targeted 
small molecule inhibitors of activated oncogenic kinases. Although the eventual emergence 
of resistance appears to be common, new research efforts are underway to reveal the 
mechanism(s) of such resistance and hopefully discover strategies to prevent disease 
progression. Collectively the past 10 years have produced unprecedented progress in 
understanding and attacking virtually every aspect of melanoma biology and clinical 
behavior. The continued characterization of melanoma mutations and risk factors will 
provide increasing opportunity to understand disease pathophysiology, and hopefully 
enable us to both meaningfully diminish melanoma risk as well as tailor treatments on the 
basis of informed molecular targeting. 
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